2. Inhibitory Antibodies
  3. Setrusumab

Setrusumab  (Synonyms: BPS 804)

Cat. No.: HY-P99398 Purity: 98.03%
COA

Molarity Calculator

Setrusumab (BPS 804) is a fully human monoclonal antibody targets sclerostin. Setrusumab efftively improves bone strength. Setrusumab can be used for the resesrch of Osteogenesis Imperfecta (OI) and cancer.

For research use only. We do not sell to patients.

Setrusumab Chemical Structure

Setrusumab Chemical Structure

CAS No. : 1847394-95-9

Size Price Stock Quantity
1 mg USD 400 In-stock
5 mg USD 1200 In-stock
10 mg USD 1900 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Setrusumab Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Setrusumab (BPS 804) is a fully human monoclonal antibody targets sclerostin. Setrusumab efftively improves bone strength. Setrusumab can be used for the resesrch of Osteogenesis Imperfecta (OI) and cancer[1].

Isotype

Human IgG2
Recommend Isotype Controls
Species

Human
In Vivo

Setrusumab (100 mg/kg; i.v. once a week for 4 weeks) inhibits breast cancer-induced bone metastases and muscle weakness in mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 8-week-old female immune-compromised CB-17/lcr-Prkdcscid/Rj mice with MDA-MB-231 breast cancer cells injection[1]
Dosage: 100 mg/kg
Administration: Intravenous injection; 100 mg/kg once a week for 4 weeks
Result: Significantly inhibited tumor growth in bones and breast cancer cell dissemination into other organs. Inhibited breast cancer-induced osteolytic lesions and subsequent loss of bone mass of the distal femur and of the proximal tibia. Redued phosphorylation of IKKα, IKKβ, and p65.
Clinical Trial
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Setrusumab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Setrusumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Setrusumab1847394-95-9BPS 804BPS804BPS-804Othersmonoclonal antibodyOIcancerbone metastasemuscle weaknessInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Setrusumab
Cat. No.:
HY-P99398
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.